Safety concerns spur FDA to again halt testing of Regenxbio gene therapy
Investigators detected masses on the spines of five patients who received its Hunter syndrome treatment, leading to the program's second clinical hold this year.
Useful takeaways from this story.
Investigators detected masses on the spines of five patients who received its Hunter syndrome treatment, leading to the program's second clinical hold this year.
Building the complete brief
The page is ready to read now. The fuller skim-friendly version will appear here automatically.
The useful part
Investigators detected masses on the spines of five patients who received its Hunter syndrome treatment, leading to the program's second clinical hold this year.
Keep reading in the app
Open the app view to save this story, compare related coverage, and continue from the same source.